CN103232973A - Method for amplification and activation of NK cells by K562 cells - Google Patents
Method for amplification and activation of NK cells by K562 cells Download PDFInfo
- Publication number
- CN103232973A CN103232973A CN2013100530840A CN201310053084A CN103232973A CN 103232973 A CN103232973 A CN 103232973A CN 2013100530840 A CN2013100530840 A CN 2013100530840A CN 201310053084 A CN201310053084 A CN 201310053084A CN 103232973 A CN103232973 A CN 103232973A
- Authority
- CN
- China
- Prior art keywords
- cell
- interleukin
- lymphocyte
- film
- amplification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a method for amplification and activation of NK cells by K562 cells. The method comprises that through synergism of K562 cells transfected by transmembrane interleukin 21, CD14, CD19, CD86 and CD137, and low-concentration interleukin 2, NK cells are subjected to directed amplification and activation. Compared with the existing similar compounds, the compound provided by the invention has a stronger lymphocyte amplification and activation capability and higher efficiency. The method has wide prospects in immunological therapy.
Description
Technical field
The invention belongs to field of immunology, specifically refer to use and stride film interleukin-22 1, CD14, CD19, the K562 cell of CD86 and CD137 transfection and lower concentration interleukin-22 acting in conjunction directed expansion activate the method for natural killer cell (NK).
Background technology
The NK cell therapy has obvious curative effects to oncotherapies such as renal cell carcinoma, melanoma, lung cancer, colorectal carcinoma, mammary cancer, bladder cancer, liver cancer and acute leukemias.At present the NK cell therapy is mainly used to and operation, chemotherapy and radiation are united use in the U.S..NK cell quantity and killing ability are directly related with curative effect, and it is very difficult that the problem that exists in the treatment is to obtain a large amount of NK cells.It is limited that the high dosage interleukin-22 that tradition is used activates the growth multiple, and telomerase activation reduces, the NK cell killing hypofunction after the amplification.Invention before our company adopts the K562 cell transfecting to stride film IL-21 and the CD137 mixture has solved this problem.With NK cell purity and the active significantly enhancing of this method amplification, quantitatively can reach the needs of clinical treatment.Yet have a large amount of TAMs (tumor-associated macrophages) and CD19+B cell in tumor microenvironment (tumor microenvironment), these cells provide nutritional factor for the growth of tumour cell.Though stride the NK cell of the K562 cell-stimulating amplification of film IL-21 and CD137 mixture with transfection only tumour cell there is very strong kill capability, very weak to the kill capability of the tumor-associated macrophages in the tumor microenvironment and B cell.
Summary of the invention
The present invention is directed to deficiency of the prior art, propose a kind of method that has more development potentiality, realize the amplification of NK cell.
The present invention is achieved by following technical proposals:
In first aspect, the invention provides a kind of method of the activated lymphocyte that increases, it is characterized in that, mixture and the interleukin-22 acting in conjunction amplification activated lymphocyte of film interleukin-22 1, CD14, CD19, CD86 and CD137 striden in use, the wherein said film interleukin-22 1 of striding is interleukin-22 1 and the mixture that the ectodomain of membranin or membranin links to each other and forms, and is preferably the mixture that interleukin-22 1 and the ectodomain of CD8 α link to each other and form; Preferably, described CD8 α, interleukin-22 1, CD14, CD19, CD86 and CD137 comprise the complete amino acid sequence of CD8 α, interleukin-22 1, CD14, CD19, CD86 and CD137 respectively or possess the aminoacid sequence fragment of its function.
In the method for amplification activated lymphocyte of the present invention, can add twice or more times strides film interleukin-22 1, CD14, CD19, CD86 and CD137 mixture, preferably, described dosage of striding film interleukin-22 1, CD14, CD19, CD86 and CD137 mixture can be 50pM-1000pM, more preferably can be 500pM～800pM.
In the method for amplification activated lymphocyte of the present invention, described mixture of striding film interleukin-22 1, CD14, CD19, CD86 and CD137 can be expressed immediately for the egg white mixture behind the purifying or by same host cell.
In the method for amplification activated lymphocyte of the present invention, described lymphocyte can be for purifying or unpurified, preferably, described lymphocyte can be that the NK cell of combination, purifying of the NK cell of NK cell, purifying of peripheral blood lymphocyte, purifying and peripheral blood lymphocyte or peripheral blood lymphocyte and other lymphocytic combination or interleukin-22 and/or interleukin-22 1 and/or CD137 mixture are injected into all white corpuscles in the blood that acts on behind the human vas, and preferably described purifying can refer to that the NK cell is more than 50% of total cellular score.
In the method for amplification activated lymphocyte of the present invention, stride film interleukin-22 1, CD14, CD19, CD86 and CD137 and can adopt protein stabilized expression system respectively, preferably, described striding in film interleukin-22 1, CD14, CD19, CD86 and the CD137 expression vector separately all can be contained viral promotors and selectable marker gene.
In the method for amplification activated lymphocyte of the present invention, described host cell can be the K562 cell; Preferably, when described film interleukin-22 1, CD14, CD19, CD86 and the CD137 mixture of striding when being expressed immediately by the K562 cell simultaneously, described K562 cell and lymphocytic usage ratio can be K562 cell: lymphocyte=1-10:1, more preferably, can be K562 cell: lymphocyte=1-4:1, most preferably can be 2: 1-3: 1.
According to each described method in the claim 1 to 6, it is characterized in that 7, the lowest dose level of wherein said interleukin-22 can be 50 units per ml, preferably, can add twice or more times described interleukin-22.
The method of amplification activated lymphocyte of the present invention, described method can comprise:
(1) in containing described lymphocytic nutrient solution, add express simultaneously stride film interleukin-22 1, CD14, CD19, CD86 and CD137 through the K562 cell of irradiation and interleukin-22 co-cultivation 7 days;
(2) medium centrifugal after will cultivating obtains cell precipitation, and uses with the nutrient solution of step (1) moderate resuspended; With
(3) add described K562 cell, cultivated 7 days;
Wherein, preferably, described nutrient solution is: the Eagle nutrient solution adds 10% human serum or 10% calf serum; Or RPMI1640 adds 10% human serum or 10% calf serum; Or F-10 (Ham ' s) Nutrient mixtures adds 10% human serum or 10% calf serum; Preferably, the dosage of described irradiation is 100Gy-1000Gy.
The method of amplification activated lymphocyte of the present invention can be dissolved in normal saline solution by the lymphocyte of described method amplification, is preferably used for intravenous drip.
In second aspect, the invention provides according to the method described in the first aspect and be used for application in the preparation at the medicine of curee's treatment cancer or communicable disease in preparation,
Wherein, preferably described curee is Mammals, more preferably is human;
Described cancer is preferably a kind of in acute myelocytic leukemia, chronic lymphatic knurl leukemia, tumor of prostate, malignant melanoma and the nephrocyte malignant tumour or at least two kinds;
Described communicable disease is preferably bacterium, virus, fungi or parasitic infection, more preferably is hepatitis B virus, hepatitis A virus (HAV), hepatitis C virus and HIV (human immunodeficiency virus) infection.As preferably, during egg white mixture after using purifying, the total dose of striding film interleukin-22 1, CD14, CD19, CD86 and CD137 of aforesaid method is at 50pM～1nM; For better realization the present invention, the total dose of striding film interleukin-22 1, CD14, CD19, CD86 and CD137 of aforesaid method is at 500pM～800pM.
As preferably, stride film interleukin-22 1, CD14, CD19, CD86 and the CD137 of aforesaid method are protein through purification process, the lymphocyte of purifying at least total number of representatives 50%.
As preferably, stride the K562 cell of film IL-21, CD14, CD19, CD86 and CD137 transfection: lymphocyte=1-10: 1.As better selection, add interleukin-22 (10-500 unit) in the lymphocyte of aforesaid method, and the K562 cell: lymphocyte=1: 1,2: 1,3: 1 or 4: 1.
As preferably, the NK cell processes of striding film interleukin-22 1, CD14, CD19, CD86 and CD137 amplification of aforesaid method is to be undertaken by the method that is dissolved in normal saline solution.
The K562 cell of striding film interleukin-22 1, CD14, CD19, CD86 and CD137 transfection among the present invention has important effect to peripheral blood lymphocytes (PBMC) and NK cell amplification with activating.The NK cell that amplification and activation back produce has important medical functions.The available sufficient amount of method that the present invention utilizes and the NK cell of function are desirable identification and the tumour cell in the destroyed tumor microenvironment, CD14+ monocyte and CD19+B cells, strengthen the immunoreactive method of patient.Tumor type is with reference to preceding patent (number of patent application: CN201110075736).The cell of pathogenic infection can also be identified and kill and wound to the NK cell, comprising but be not limited to: hepatitis B virus, hepatitis A virus (HAV), hepatitis C virus and virus of AIDS.
Stride whole polypeptide that film interleukin-22 1, CD14, CD19, CD86, CD137, CD8 α and interleukin-22 are this protein among the present invention, wherein also comprise the polypeptide composition that possesses function in these protein.Peripheral blood lymphocytes among the present invention comes from peripheral blood, and Cord blood and marrow are the tissues that breaks away from human body.Being used for expanded cells among the present invention can be the NK cell; It also can be the various combination of NK cell and peripheral blood lymphocytes; Also can be NK cell or peripheral blood lymphocytes and other lymphocytic various combination; Also can be that interleukin-22 and/or interleukin-22 1 and/or CD14 and/or CD19 and/or CD86 and/or CD137 mixture are injected into all leukocytic summations in the blood that acts on behind the human vas.Interleukin-22 among the present invention, interleukin-22 1, CD14, CD19, CD86 and CD137 derive from the people, but be not limited only to the people, as injection or handle to as if other species, as mouse, rat, monkey etc. also can be interleukin-22, interleukin-22 1, CD14, CD19, CD86 and the CD137 of other species.
Except as otherwise noted, the implication of all technology and science vocabulary is the implication of the personage's common sense with common skill in the industry among the present invention.Being defined in all molecular biology books of Essential Terms can be found, for example, and Benjamin Lewin, Genes VIII, Oxford University Press, 2004 (ISBN 0-13-145140-5).
In order to ensure for a long time, production recombinant interleukin 21, CD14, CD19, CD86 and the CD137 of high yield, the present invention has adopted protein stabilized expression system.Make up protein stabilized expression system and be the institute of the personage with common skill technology of employing usually in the industry, concrete grammar can see for details (Leukemia such as Imai, 2004,18,676-684).For example, K562 clone has been transcribed the expression vector that stably express is striden film interleukin-22 1, CD14, CD19, CD86 and CD137, contains viral promotors and selectable marker gene in this carrier, as antibiotics resistance gene.CD8 α is a kind of membranin of expressing at cytolemma, and CD8 α gene makes interleukin-22 1 be expressed on the cytolemma after connecting interleukin-22 1 gene, becomes transmembrane protein; CD14, CD19, CD86 and CD137 are membranin.After the heterogenous expression carrier enters host cell, activate promotor with appropriate methods, culturing cell namely can obtain interleukin-22 1, CD14, CD19, CD86 and the CD137 polypeptide of high level expression on cytolemma after for some time.These methods are methods of the personage's common sense with common skill in the industry.
The cell that high level expression is striden film interleukin-22 1, CD14, CD19, CD86 and CD137 on the K562 cytolemma can be collected by ultracentrifugal method, the K562 cell can include but not limited to following listed method processing by these technology: strong acid, highly basic and irradiation.Cell after the processing can be directly and peripheral blood lymphocyte (PBMC) or NK cell co-cultivation, activates amplification NK cell, also can purifies and separates after with the PBMC co-cultivation, activate amplification NK cell.
High level expression strides film interleukin-22 1, CD14, CD19, CD86 and CD137 and can come purifying and separate by the technology that the personage was familiar with common skill in the industry on cytolemma.These technology include but not limited to following listed method: ammonium sulfate or ethanol sedimentation, acid extraction, negatively charged ion or cation-exchange chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography method, chromatography and lectin.If necessary, the scheme of protein renaturation can be used to help purifying expressed proteins polypeptide.If necessary, high performance liquid chromatography (HPLC) can be made last purification step and be further purified protein.Stride film interleukin-22 1, CD14, CD19, CD86 and CD137 at host cell inner expression among the present invention understand some and are secreted in the cell culture supernatant.The personage with common skill in the industry can verify according to common Measurement for Biochemistry.Be secreted in the cell culture supernatant stride film interleukin-22 1, CD14, CD19, CD86 and CD137 also can by the aforesaid method purifying with separate.
Cytolemma provides solid phase support for striding film interleukin-22 1, CD14, CD19, CD86 and CD137, and described solid phase support comprises but is not limited only to metal, glass, plastics, polymkeric substance, particle, molecule, phosphatide, phospholipid bilayer, cytolemma and analogue.Importantly the surface of solid phase can adhere to and state protein.
Striding the method for the manipulation nucleotide coding sequence that film interleukin-22 1, CD14, CD19, CD86 and CD137 also can be by standard produces.For example, with specific, unspecific rite-directed mutagenesis or other Protocols in Molecular Biologies are produced functional equivalent, but primary structure polypeptide inequality.If simple one or more amino acid is revised the biochemical characteristic that does not influence protein, these guard the protein of replacement generation also within the scope of protection of the invention by amino acid.
The NK cell of the K562 cell amplification of film interleukin-22 1, CD14, CD19, CD86 and CD137 is striden in transfection among the present invention, can be used for carrying out autotransplantation, also can carry out heteroplastic transplantation.Under the histocompatibility antigen that is subjected to contributor (grownup or minor) and blood antigen and contributor's (grownup or minor) histocompatibility antigen and prerequisite that blood antigen is complementary, the contributor is activated and expanded cells can be injected into by the mode of intravenous drip by in contributor's the blood vessel.In some applications, clone (for example, NK clone, NKT clone) also can activate by the K562 cell that film interleukin-22 1, CD14, CD19, CD86 and CD137 are striden in transfection and increase.Expanded cells system also is protection scope of the present invention for the preparation of the medicine for the treatment of disease.
Lymphocyte or lymphocyte precursor cell can be from deriving from any tissue that includes big amount lymphocyte and precursor cell.For example, peripheral blood (comprising Cord blood), marrow, spleen and lymphoglandula.Lymphocyte or lymphocyte precursor cell are taken from peripheral blood or marrow usually.In other are used (for example, experimental study), spleen and/or lymphoglandula also are suitable sources.
For example, lymphocyte can be by taking out peripheral blood and/or marrow obtains.Lymphocyte can further obtain NK cell and NKT cell through purifying.Purifying NK cell, the step of NKT cell and technology are that the personage with common skill in the industry is familiar with.Lymphocyte can come erythrocyte in separating blood or the marrow by the mode of density gradient centrifugation, lymphocyte and other cells.NK cell and NKT cell can utilize antibody-mediated affine preparation method to be further purified, for example the antibodies paramagnetic particle method.The purifying lymphocyte does not also require that the lymphocyte of purifying is definitely pure, and refers to that the cell of purifying is higher than its ratio shared in coming source tissue.Generally, the lymphocyte of purifying at least total number of representatives 50%, perhaps 60%, perhaps higher.The NK cell of purifying and NKT cell suspension are in a suitable physiological buffer solution, then suspension growth in but be not limited in the following nutrient solution, Eagle ' s nutrient solution adds 10% human serum, RPMI 1640 adds 10% human serum, and (Ham ' s) Nutrient mixtures adds 10% human serum to F-10.Human serum also can replace with 10% foetal calf serum, but human serum is better to the expanding effect of NK cell.
The lymphocyte of lymphocyte and/or purifying and/or lymphocyte precursor cell suspension grow in the cell culture fluid, K562 cell and the cultivation of low dosage interleukin-22 of film interleukin-22 1, CD14, CD19, CD86 and CD137 striden in transfection behind the adding irradiation, adds the K562 cell that film interleukin-22 1, CD14, CD19, CD86 and CD137 are striden in new transfection weekly.Generally in order to reduce cost and to avoid infection, the present invention adopts the minimum doses NK lymphocyte that increases.The dosage of interleukin-22 in 50 units per ml between 1000 units per ml.In some cases, the dosage of interleukin-22 mixture is at least more than 500 units per ml.In some cases, be necessary to carry out the processing of high dosage, activate concentration and be about 500 units per ml or 1000 units per ml.In addition, stride film interleukin-22 1, CD14, CD19, CD86, CD137 and be injected directly into human body, when being used for increasing in vivo the NK cell, used dosage at 0.5pM between the 0.5nM.Transfection is striden the employing dosage of the K562 cell of film interleukin-22 1, CD14, CD19, CD86 and CD137 and is determined according to striding film interleukin-22 1, CD14, CD19, CD86, the CD137 expression dosage in K562.In some cases, according to K562: peripheral blood lymphocytes=1: 1,2: 1,3: 1, the K562 cell of film interleukin-22 1, CD14, CD19, CD86 and CD137 was striden in 4: 1 or above adding transfection.In some cases, be necessary to carry out the processing of high dosage, according to K562: the K562 cell of film interleukin-22 1, CD14, CD19, CD86 and CD137 is striden in peripheral blood lymphocytes=10: 1 or above adding transfection.Can transplant to monocytic contributor itself or be subjected to the contributor at the NK of amplification in vitro cell, to strengthen born or the antigen specific immune reaction.Generally, the NK cell of amplification is by being dissolved in the method intravenous drip of normal saline solution.
Beneficial effect:
(1) the present invention is on the basis of the K562 cell of striding film interleukin-22 1 and CD137, transfection CD14, CD19 and CD86.The CD14 of transfection helps to activate NK cell recognition and killing tumor cells associated macrophages on the K562 cell; Transfection CD19 helps to activate the NK cell recognition and kills and wounds the B cell; Transfection CD86 helps to promote the NK cell to the lethal effect of the tumor-associated macrophages in tumour cell, the microenvironment and the B cell in the microenvironment.
(2) the invention provides the method for amplification in vitro and activation NK than using only transfection to stride the method for the K562 cell-stimulating amplification NK cell of film interleukin-22 1 and CD137, the efficient of amplification is high 2.4 times, and the NK cell after the amplification has improved 2.7 times to the kill capability of tumor-associated macrophages.Experimentation on animals is the result show: compare with the NK cell of using only transfection to stride the K562 cell-stimulating amplification of film interleukin-22 1 and CD137, the NK cell that adopts the present invention to increase has significantly improved the kill capability to mouse interior tumor.
(3) the present invention strides the K562 cell of film interleukin-22 1, CD14, CD19, CD86 and CD137 and low dosage interleukin-22 by transfection and cultivates immunizing power that NK that amplification activates improves patient and help patient and resist tumour, opposing virus and bacterium.
Description of drawings
Fig. 1 is that host cell is expressed the structural representation of striding film interleukin-22 1, CD14, CD19, CD86 and CD137 simultaneously among the present invention;
Fig. 2 NK cell expansion ex vivo linear graph, show that K562 cell and low dosage interleukin-22 acting in conjunction lower linear that the NK lymphocyte is striden film interleukin-22 1, CD14, CD19, CD86 and CD137 in transfection increase, the K562 cell amplification NK cell that film interleukin-22 1 and CD137 are striden in transfection in contrast;
Fig. 3 PBMC cell expansion ex vivo linear graph, show that K562 cell and low dosage interleukin-22 acting in conjunction lower linear that lymphocyte is striden film interleukin-22 1, CD14, CD19, CD86 and CD137 in transfection increase, the K562 cell amplification lymphocyte that film interleukin-22 1 and CD137 are striden in transfection in contrast;
Stream shows the instrument data plot before and after Fig. 4 PBMC cell expansion ex vivo, the PBMC cell transfection stride cultivate 14 days under the K562 cell of film interleukin-22 1, CD14, CD19, CD86 and CD137 and the acting in conjunction of low dosage interleukin-22 after NK cell (CD56+, CD16+ and CD56+/CD16+) the ratio phenomenal growth, the K562 cell amplification PBMC cell that film interleukin-22 1 and CD137 are striden in transfection is in contrast;
Fig. 5 NK cell killing tumour cell figure, human PBMC's cell is striden under the K562 cell and the acting in conjunction of low dosage interleukin-22 of film interleukin-22 1, CD14, CD19, CD86 and CD137 in transfection, cultivate after 14 days the NK cell to the lethal effect of K562 tumour cell, transfection stride among the K562 cell amplification PBMC of film interleukin-22 1 and CD137 the NK cell in contrast;
Fig. 6 NK cell killing TAM cell, human PBMC's cell is striden under the K562 cell and the acting in conjunction of low dosage interleukin-22 of film interleukin-22 1, CD14, CD19, CD86 and CD137 in transfection, cultivate after 14 days the NK cell to the lethal effect of TAM cell, transfection stride among the K562 cell amplification PBMC of film interleukin-22 1 and CD137 the NK cell in contrast;
Fig. 7 increases and activates the back NK cells of human beings to the lethal effect figure of PC3 tumor cell line in the mouse body, transfection is striden under the K562 cell and the acting in conjunction of low dosage interleukin-22 of film interleukin-22 1, CD14, CD19, CD86 and CD137, cultivate that the NK cell has stronger lethal effect to the PC3 cell in the mouse body after 14 days, the NK cell that transfection is striden among the K562 cell amplification PBMC of film interleukin-22 1 and CD137 is schemed in contrast;
The NK cytological map among the amplification PBMC under the K562 cell of film interleukin-22 1, CD14, CD19, CD86 and CD137 and the acting in conjunction of low dosage interleukin-22 is striden in Fig. 8 transfection, cultivate NK cell after 14 days and significantly improve the survival rate of mice with tumor and prolong the mouse mean lifetime, the NK cell that transfection is striden among the K562 cell amplification PBMC of film interleukin-22 1 and CD137 is schemed in contrast.
Embodiment
Further specify technical scheme of the present invention below in conjunction with accompanying drawing and by embodiment.
Below enforcement of the present invention is specified:
Transcribe stably express with K562 clone and stride the expression vector of film interleukin-22 1, CD14, CD19, CD86 and CD137 (referring to Fig. 1), the membranin of CD8 α for expressing at cytolemma, CD8 α gene makes interleukin-22 1 be expressed on the cytolemma after connecting interleukin-22 1 gene, become transmembrane protein, and CD14, CD19, CD86 and CD137 are membranin, and its carrier separately contains viral promotors and selectable marker gene in respectively; After the heterogenous expression carrier enters host cell, activate promotor, cultivate K562 cell for some time, namely can obtain interleukin-22 1, CD14, CD19, CD86 and CD137 polypeptide on cytolemma simultaneously; Have simultaneously on the K562 cytolemma after cultivating and express the cell of striding film interleukin-22 1, CD14, CD19, CD86 and CD137, by strong acid, highly basic and/or irradiation, and collect the K562 cell by high speed centrifugation; Or to the K562 cell successively with ammonium sulfate or ethanol sedimentation, strong acid extracts, negatively charged ion or cation-exchange chromatography, hydrophobic interaction chromatography, affinity chromatography, the hydroxylapatite chromatography method, chromatography and lectin carry out purifying and collect; With combination or NK cell and lymphocytic combination or peripheral blood lymphocytes and other lymphocytic combination or interleukin-22 and/or interleukin-22 1 and/or CD14 and/or CD19 and/or CD86 and/or the CD137 of the K562 cell of above-mentioned centrifugal collection and NK cell or NK cell and peripheral blood lymphocytes and co-cultivation is carried out in leukocytic combination or behind purifies and separates K562 cell with the PBMC co-cultivation, activate amplification NK cell, until more than 50% of NK cell total number of representatives.
Get NK cell (2x107) and cultivate in RPMI1640, be aided with 10% human serum.The K562 nurse cell of adding transfection CD8 α-interleukin-22 1, CD14, CD19, CD86 and CD137 (100Gy) and behind the interleukin-22 (50 units per ml) cultivated 7 days by irradiation in nutrient solution.Centrifugal after 7 days, resuspended with the nutrient solution of equivalent, add K562 cell through transfection CD8 α-interleukin-22 1, CD14, CD19, CD86 and the CD137 of irradiation (Leukemia such as Imai, 2004,18,676-684), cultivated again 7 days, as shown in Figure 1.High dosage interleukin-22 (200 units per ml) is organized in contrast.As shown in Figure 1, the NK cell is under the acting in conjunction of the K562 cell of transfection CD8 α-interleukin-22 1, CD14, CD19, CD86 and CD137 and low dosage interleukin-22, and quantity significantly increases.The increase of cell quantity can be measured by the method for inserting thymidine.Cell continued to cultivate 12 hours after thymidine inserted, and then the variation that begins to measure cell quantity.At K562: enter logarithmic phase when the NK cell quantity was at 7 days under the effect of NK lymphocyte=1: 1 concentration, 14 days the time increased by 2200 times approximately.After adding nurse cell, the NK cell can begin to increase under the interleukin-22 effect of 50 units per ml.The K562 nurse cell of transfection CD8 α-interleukin-22 1, CD14, CD19, CD86 and CD137 obviously is better than transfection for the effect that promotes the growth of NK cell and strides the K562 nurse cell of film interleukin-22 and CD137 (14 days time strong approximately 2.4 times).
The not purified peripheral blood lymphocyte of embodiment 2 amplifications
The K562 nurse cell of transfection CD8 α-interleukin-22 1, CD14, CD19, CD86 and CD137 not only can amplification purification the NK cell, not purified lymphocyte can also increase.The healthy people's of donation PBMC cultivates in RPMI1640, is aided with 10% human serum.(irradiation, co-cultivation is 7 days 100Gy) and behind the low dosage interleukin-22 to add the K562 nurse cell of transfection CD8 α-interleukin-22 1, CD14, CD19, CD86 and CD137 in nutrient solution.Centrifugal after 7 days, resuspended with the nutrient solution of equivalent, add the nurse cell through 100Gy irradiation, cultivated again 7 days, as shown in Figure 2.The K562 nurse cell of transfection CD8 α-interleukin-22 1 and CD137 in contrast.The NK cell is under the acting in conjunction of the K562 nurse cell of transfection CD8 α-interleukin-22 1, CD14, CD19, CD86 and CD137 and low dosage interleukin-22, and quantity significantly increases.The NK cell quantity entered logarithmic phase in the time of 7 days, 14 days the time increased by 2100 times approximately.The K562 nurse cell of transfection CD8 α-interleukin-22 1, CD14, CD19, CD86 and CD137 obviously is better than transfection for the effect that promotes NK cell growth in the peripheral blood lymphocyte and strides the K562 nurse cell of film interleukin-22 and CD137 (14 days time, 2.1 times).
Under the K562 nurse cell and the acting in conjunction of low dosage interleukin-22 of transfection CD8 α-interleukin-22 1, CD14, CD19, CD86 and CD137, in the time of the 14th day 95% lymphocyte become the NK cell (CD56+, CD16+, CD56+/CD16+), as shown in Figure 3.Cellular control unit under the K562 nurse cell effect of transfection CD8 α-interleukin-22 1 and CD137, peripheral blood lymphocyte have 91% cell become the NK cell (CD56+, CD16+, CD56+/CD16+).
NK cell after embodiment 3 amplifications is to the splitting action of tumour cell and TAM (tumor-associated macrophages)
The NK cell that increases under the K562 nurse cell of transfection CD8 α-interleukin-22 1, CD14, CD19, CD86 and CD137 and the acting in conjunction of low dosage interleukin-22 is to the splitting action of tumour cell
Studies show that to the injected in mice interleukin-22 of suffering from tumour in the past can strengthen the anti-tumor capacity of mouse, delays the life-span of mouse.The NK cell that increases under the K562 nurse cell of present embodiment employing transfection CD8 α-interleukin-22 1, CD14, CD19, CD86 and CD137 and the acting in conjunction of low dosage interleukin-22 and the method for tumour cell and tumor-associated macrophages co-cultivation, the NK cell of studying with amplification carries out antineoplastic feasibility.Present embodiment adopts the method for the NK injection cell mouse interior therapeutic mouse interior tumor that increases under the K562 nurse cell of transfection CD8 α-interleukin-22 1, CD14, CD19, CD86 and CD137 and the acting in conjunction of low dosage interleukin-22, studies the antineoplastic effect of NK cell of amplification.
After separating in the lymphocyte with healthy donor, the NK cell growth of increasing under the K562 nurse cell of adding transfection CD8 α-interleukin-22 1, CD14, CD19, CD86 and CD137 and the acting in conjunction of low dosage interleukin-22 14 days.K562 and tumor-associated macrophages are used as the target cell of cracking.K562 is B cell tumour clone, and this clone is blood tumor cell system.IL-4, the monocyte after IL-10 and IL-13 handle is converted into the target cell that tumor-associated macrophages is used as cracking.The NK cell of amplification and target cell co-cultivation in accordance with the appropriate ratio detect the target cell that survives after 6 hours.The NK cell of the K562 nurse cell amplification of transfection CD8 α-interleukin-22 1 and CD137 is organized in contrast.
The NK cell of the K562 nurse cell amplification of transfection CD8 α-interleukin-22 1, CD14, CD19, CD86 and CD137 is suitable to the lethal effect of K562 target cell with control group NK cell, lethal effect to tumor-associated macrophages then significantly strengthens, p＜0.05, as shown in Figure 5.
The PC3 clone of external use Lentivirus system constructing Fluc reporter gene stably express.Fluc Lentivirus system is available from System Biosciences (U.S., California), and concrete construction process sees product introduction for details.Serious immunodeficient mouse (NOD/SCID) is advanced in the intravenous injection of PC3-Fluc cell, and fluorimetric detector detects growth of tumor situation, random packet after 21 days.NK cell after the amplification is according to 1x10
7Cell/every mouse is from tail vein injection, biweekly.Stop treatment after continuously around the treatment, observe result for the treatment of.Fig. 6 shows the fluorescent signal for the treatment of tumour reporter gene after 14 days.The NK cell of the K562 nurse cell amplification of transfection CD8 α-interleukin-22 1 and CD137 has certain restraining effect to the growth of tumour cell.The NK cell of the K562 nurse cell amplification of transfection CD8 α-interleukin-22 1, CD14, CD19, CD86 and CD137 is stronger than the lethal effect of control group NK cell PC3 tumour cell.Fig. 7 shows that the NK cell of control group has certain effect to the survival rate that prolongs mouse.And compare with control group, the NK cell of the K562 nurse cell of transfection CD8 α-interleukin-22 1, CD14, CD19, CD86 and CD137 amplification has significantly improved the curative ratio to tumour, significant prolongation the survival rate of mouse.The NK cell of the K562 nurse cell amplification of this prompting transfection CD8 α-interleukin-22 1, CD14, CD19, CD86 and CD137 can be used for clinical oncotherapy.
A scheme that can be used for making medicine is provided in an embodiment of the present invention, and the medicine of making according to this scheme can have following described multiple use.This scheme comprises interleukin-22, interleukin-22 1, CD14, CD19, CD86 and CD137.Utilize the NK cell of this programme amplification to be applicable to the various sights that need to strengthen patient's immunizing power.For example, amplification NK cell is effective especially to the treatment tumour, as acute myelocytic leukemia, and chronic lymphatic knurl leukemia, tumor of prostate, malignant melanoma and nephrocyte malignant tumour, but be not limited only to above-mentioned tumour.For example, amplification NK cell infects effective especially to the treatment bacterium in fungi or the parasite.The NK cell of amplification is effective especially to the treatment virus infection, as hepatitis B virus, and hepatitis A virus (HAV), hepatitis C virus and virus of AIDS but be not limited only to above-mentioned virus infection.The NK cell of amplification can significantly improve the action effect of antigen.
The K562 cell of transfection CD8 α-interleukin-22 1, CD14, CD19, CD86 and the CD137 NK cell that can be used to increase among the present invention also can transplant patient.The NK cell portable patient of amplification in vitro.For example, the method that CD8 α-interleukin-22 1, CD14, CD19, CD86, CD137 and the amplification of low dosage interleukin-22 activate the NK cell is than with the method for the K562 cell-stimulating amplification NK cell of transfection CD8 α-interleukin-22 1 and CD137 only, and the efficient of amplification is high 2.4 times.After fortnight, the purity of NK cell can reach 95%, and the quantity of cell can reach 1.0x10
10More than, satisfy the demand of clinical treatment, as shown in Figure 4.
Applicant's statement, the present invention illustrates detailed features of the present invention and method by above-described embodiment, but the present invention is not limited to above-mentioned detailed features and method, does not mean that namely the present invention must rely on above-mentioned detailed features and method could be implemented.The person of ordinary skill in the field should understand; any improvement in the present invention; to the increase of the equivalence replacement of the selected material of the present invention and step and subsidiary material and step, the selection of concrete mode etc., all drop within protection scope of the present invention and the open scope.
Claims (10)
1. the method for the activated lymphocyte that increases, it is characterized in that, mixture and the interleukin-22 acting in conjunction amplification activated lymphocyte of film interleukin-22 1, CD14, CD19, CD86 and CD137 striden in use, the wherein said film interleukin-22 1 of striding is interleukin-22 1 and the mixture that the ectodomain of membranin or membranin links to each other and forms, and is preferably the mixture that interleukin-22 1 and the ectodomain of CD8 α link to each other and form; Preferably, described CD8 α, interleukin-22 1, CD14, CD19, CD86 and CD137 comprise the complete amino acid sequence of CD8 α, interleukin-22 1, CD14, CD19, CD86 and CD137 respectively or possess the aminoacid sequence fragment of its function.
2. method according to claim 1, it is characterized in that, add in the described method twice or stride film interleukin-22 1, CD14, CD19, CD86 and CD137 mixture more frequently, preferably, described dosage of striding film interleukin-22 1, CD14, CD19, CD86 and CD137 mixture is 50pM-1000pM, more preferably 500pM～800pM.
3. method according to claim 1 and 2 is characterized in that, described mixture of striding film interleukin-22 1, CD14, CD19, CD86 and CD137 is the egg white mixture behind the purifying or is expressed immediately by same host cell.
4. according to each described method in the claim 1 to 3, it is characterized in that, described lymphocyte is purifying or unpurified, preferably, described lymphocyte is that the NK cell of combination, purifying of the NK cell of NK cell, purifying of peripheral blood lymphocyte, purifying and peripheral blood lymphocyte or peripheral blood lymphocyte and other lymphocytic combination or interleukin-22 and/or interleukin-22 1 and/or CD137 mixture are injected into all white corpuscles in the blood that acts on behind the human vas, and preferably described purifying refers to that the NK cell is more than 50% of total cellular score.
5. according to each described method in the claim 1 to 4, it is characterized in that, stride film interleukin-22 1, CD14, CD19, CD86 and CD137 and adopt protein stabilized expression system respectively, preferably, described striding in film interleukin-22 1, CD14, CD19, CD86 and the CD137 expression vector separately all contained viral promotors and selectable marker gene.
6. method according to claim 3 is characterized in that, described host cell is the K562 cell; Preferably, when described film interleukin-22 1, CD14, CD19, CD86 and the CD137 mixture of striding when being expressed immediately by the K562 cell simultaneously, described K562 cell and lymphocytic usage ratio are K562 cell: lymphocyte=1-10:1, more preferably, be K562 cell: lymphocyte=1-4:1, be most preferably 2: 1-3: 1.
7. according to each described method in the claim 1 to 6, it is characterized in that the lowest dose level of wherein said interleukin-22 is 50 units per ml, preferably, add twice or more times described interleukin-22.
8. method according to claim 1 is characterized in that, described method comprises:
(1) in containing described lymphocytic nutrient solution, add express simultaneously stride film interleukin-22 1, CD14, CD19, CD86 and CD137 through the K562 cell of irradiation and interleukin-22 co-cultivation 7 days;
(2) medium centrifugal after will cultivating obtains cell precipitation, and uses with the nutrient solution of step (1) moderate resuspended; With
(3) add described K562 cell, cultivated 7 days;
Wherein, preferably, described nutrient solution is: the Eagle nutrient solution adds 10% human serum or 10% calf serum; Or RPMI1640 adds 10% human serum or 10% calf serum; Or F-10 (Ham ' s) Nutrient mixtures adds 10% human serum or 10% calf serum; Preferably, the dosage of described irradiation is 100Gy-1000Gy.
9. according to each described method among the claim 1-8, it is characterized in that the lymphocyte that increases by described method is dissolved in normal saline solution, is preferably used for intravenous drip.
10. be used for application in the preparation at the medicine of curee's treatment cancer or communicable disease according to each described method among the claim 1-9 in preparation,
Wherein, preferably described curee is Mammals, more preferably is human;
Described cancer is preferably a kind of in acute myelocytic leukemia, chronic lymphatic knurl leukemia, tumor of prostate, malignant melanoma and the nephrocyte malignant tumour or at least two kinds;
Described communicable disease is preferably bacterium, virus, fungi or parasitic infection, more preferably is hepatitis B virus, hepatitis A virus (HAV), hepatitis C virus and HIV (human immunodeficiency virus) infection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310053084.0A CN103232973B (en) | 2012-03-12 | 2013-02-19 | A kind of K562 cell amplification activates the method for NK cell |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210063090.X | 2012-03-12 | ||
| CN201210063090X | 2012-03-12 | ||
| CN201210063090XA CN102586185A (en) | 2012-03-12 | 2012-03-12 | Method for amplifying and activating NK (Natural Killer) cells by K562 cells |
| CN201310053084.0A CN103232973B (en) | 2012-03-12 | 2013-02-19 | A kind of K562 cell amplification activates the method for NK cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103232973A true CN103232973A (en) | 2013-08-07 |
| CN103232973B CN103232973B (en) | 2016-06-22 |
Family
ID=46475421
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210063090XA Pending CN102586185A (en) | 2012-03-12 | 2012-03-12 | Method for amplifying and activating NK (Natural Killer) cells by K562 cells |
| CN201310053084.0A Active CN103232973B (en) | 2012-03-12 | 2013-02-19 | A kind of K562 cell amplification activates the method for NK cell |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210063090XA Pending CN102586185A (en) | 2012-03-12 | 2012-03-12 | Method for amplifying and activating NK (Natural Killer) cells by K562 cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN102586185A (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104894072A (en) * | 2015-06-25 | 2015-09-09 | 紫程瑞生会(北京)生物技术发展有限公司 | Preparation method and application of autologous natural killer cell proliferation |
| CN105624107A (en) * | 2015-09-21 | 2016-06-01 | 深圳市科晖瑞生物医药有限公司 | Expansion method of various lymphocyte subpopulations and application of expansion method |
| CN105647864A (en) * | 2016-03-15 | 2016-06-08 | 浙江大学 | Amplification and activation method of iNKT (invariant natural killer T) lymphocyte |
| CN105647863A (en) * | 2016-03-15 | 2016-06-08 | 浙江大学 | Method for amplifying and activating LAK cells by non-fetus bovine serum |
| CN105695404A (en) * | 2016-03-15 | 2016-06-22 | 浙江大学 | Method for amplifying and activating CIK lymphocyte |
| CN106497952A (en) * | 2016-11-03 | 2017-03-15 | 河南省华隆生物技术有限公司 | A kind of based on the film ankyrin of CD86, its preparation method and application |
| WO2017059796A1 (en) * | 2015-10-08 | 2017-04-13 | Shanghai Sidansai Biotechnology Co., Ltd | Activation and expansion of t cells |
| CN107177548A (en) * | 2017-06-26 | 2017-09-19 | 杭州中赢生物医疗科技有限公司 | A kind of cultivating system of amplification in vitro lymphocyte and amplification method and application |
| CN110951684A (en) * | 2019-12-20 | 2020-04-03 | 吉林省中科生物工程股份有限公司 | Human peripheral blood NK cell culture system and culture method |
| CN112608901A (en) * | 2020-12-21 | 2021-04-06 | 广东昭泰体内生物医药科技有限公司 | Artificial antigen presenting cell and preparation method and application thereof |
| CN113151167A (en) * | 2014-10-27 | 2021-07-23 | 弗罗里达中央大学研究基金会 | Methods and compositions for natural killer cells |
| CN114058584A (en) * | 2022-01-07 | 2022-02-18 | 山东省齐鲁干细胞工程有限公司 | Preparation method of natural killer cells for clinical use |
| CN114686429A (en) * | 2020-12-31 | 2022-07-01 | 中国科学院分子细胞科学卓越创新中心 | Tumor immunotherapy method for activating NK cells |
| CN115247149A (en) * | 2022-08-22 | 2022-10-28 | 华域生物科技(天津)有限公司 | Culture medium composition suitable for NK cells and culture method |
| RU2803178C1 (en) * | 2022-12-08 | 2023-09-07 | Общество с ограниченной ответственностью "Текон Медицинские приборы" | Recombinant cell line tmdk562-15 showing the ability to activate and proliferate human nk cells |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102994449A (en) * | 2012-12-13 | 2013-03-27 | 上海柯莱逊生物技术有限公司 | Method for in-vitro amplification of NK cells |
| WO2014155572A1 (en) * | 2013-03-27 | 2014-10-02 | 株式会社日本バイオセラピー研究所 | Method for producing nk cell-enhancing blood product |
| CN103243072B (en) * | 2013-05-09 | 2016-03-02 | 杭州中赢生物医疗科技有限公司 | The method of CD8 α-interleukin-22 1 fragment-CD137 mixture amplification activated lymphocyte |
| CN105524880A (en) * | 2016-01-27 | 2016-04-27 | 上海润泉生物技术有限公司 | Construction method of immune cell bank |
| CN109153974A (en) * | 2016-03-04 | 2019-01-04 | 张明杰 | Enhance the composition to abnormal cell lethality and its application |
| CN106085957B (en) * | 2016-06-15 | 2017-06-06 | 浙江生创精准医疗科技有限公司 | A kind of three-dimensional amplification of microcarrier and the method for activating NK |
| CN108300697A (en) * | 2017-01-13 | 2018-07-20 | 上海恒润达生生物科技有限公司 | A kind of method and purposes that trophocyte stimulation NK cells expand |
| CN108300693A (en) * | 2018-01-25 | 2018-07-20 | 河北省健海生物芯片技术有限责任公司 | A kind of natural killer cells amplification in vitro method |
| CN109055310A (en) * | 2018-07-03 | 2018-12-21 | 湖南未名三胞转化医学科技有限公司 | A kind of NK cell culture processes based on TWS119 |
| CN109668819A (en) * | 2019-02-01 | 2019-04-23 | 上海市公共卫生临床中心 | The kit and its application method of a kind of evaluation of body's immunity and application |
| CN111544585A (en) * | 2019-02-11 | 2020-08-18 | 北京卡替医疗技术有限公司 | Adjuvant capable of boosting immune cells to expand in vivo |
| CN110951694B (en) * | 2019-12-30 | 2021-07-06 | 北京鼎成肽源生物技术有限公司 | Preparation method of autologous trophoblast and culture method of SNK cells |
| CN111358953A (en) * | 2020-03-25 | 2020-07-03 | 上海市公共卫生临床中心 | Vaccine vector for efficiently inducing humoral immune response of organism, preparation method and application thereof |
| CN112501127B (en) * | 2020-12-21 | 2023-10-10 | 广东昭泰细胞生物科技有限公司 | Culture method of reprogramming NK cells |
| CN112626028B (en) * | 2020-12-21 | 2023-11-21 | 广东昭泰细胞生物科技有限公司 | Engineering cell for activating NK-like cells and preparation method and application thereof |
| CN112695014A (en) * | 2020-12-23 | 2021-04-23 | 杭州中赢生物医疗科技有限公司 | Culture system and culture method for amplifying NK cells |
| CN112725273A (en) * | 2021-01-27 | 2021-04-30 | 河南省华隆生物技术有限公司 | NK cell and preparation method and application thereof |
| CN112779224A (en) * | 2021-01-27 | 2021-05-11 | 河南省华隆生物技术有限公司 | NK trophoblast cell expressing cytokine composition and preparation method and application thereof |
| CN112725284A (en) * | 2021-01-27 | 2021-04-30 | 河南省华隆生物技术有限公司 | NK trophoblast cell and application thereof |
| CN112852744A (en) * | 2021-01-27 | 2021-05-28 | 河南省华隆生物技术有限公司 | NK trophoblast cell and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101735982A (en) * | 2009-12-31 | 2010-06-16 | 浙江中赢控股集团有限公司 | Method for amplifying lymphocyte by interleukin 15 receptor and interleukin 2 complex |
| CN102154207A (en) * | 2011-03-28 | 2011-08-17 | 浙江中赢干细胞生物工程股份有限公司 | Method for amplifying and activating lymphocyte by using CD8 alpha-interleukin 21-CD137 compound |
-
2012
- 2012-03-12 CN CN201210063090XA patent/CN102586185A/en active Pending
-
2013
- 2013-02-19 CN CN201310053084.0A patent/CN103232973B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101735982A (en) * | 2009-12-31 | 2010-06-16 | 浙江中赢控股集团有限公司 | Method for amplifying lymphocyte by interleukin 15 receptor and interleukin 2 complex |
| CN102154207A (en) * | 2011-03-28 | 2011-08-17 | 浙江中赢干细胞生物工程股份有限公司 | Method for amplifying and activating lymphocyte by using CD8 alpha-interleukin 21-CD137 compound |
Non-Patent Citations (3)
| Title |
|---|
| DUCK CHO 等: "EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS FOR CANCER IMMUNOTHERAPY", 《KOREAN JOURNAL OF LABORATORY MEDICINE》 * |
| 李文建等: "重离子辐射哺乳动物细胞敏感性的分子机理", 《原子核物理评论》 * |
| 龚伊红 等: "基因重组人白细胞介素21体外对NK细胞活性的影响", 《医学研究通讯》 * |
Cited By (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113151167A (en) * | 2014-10-27 | 2021-07-23 | 弗罗里达中央大学研究基金会 | Methods and compositions for natural killer cells |
| CN104894072B (en) * | 2015-06-25 | 2018-04-17 | 紫程瑞生会(北京)生物技术发展有限公司 | A kind of preparation method and applications of autologous natural killer cells propagation |
| CN104894072A (en) * | 2015-06-25 | 2015-09-09 | 紫程瑞生会(北京)生物技术发展有限公司 | Preparation method and application of autologous natural killer cell proliferation |
| CN105624107A (en) * | 2015-09-21 | 2016-06-01 | 深圳市科晖瑞生物医药有限公司 | Expansion method of various lymphocyte subpopulations and application of expansion method |
| CN105624107B (en) * | 2015-09-21 | 2020-06-12 | 杭州优善生物科技有限公司 | Amplification method of multiple lymphocyte subsets and application thereof |
| CN108138148A (en) * | 2015-10-08 | 2018-06-08 | 上海斯丹赛生物技术有限公司 | The activation and amplification of T cell |
| WO2017059796A1 (en) * | 2015-10-08 | 2017-04-13 | Shanghai Sidansai Biotechnology Co., Ltd | Activation and expansion of t cells |
| CN105647864B (en) * | 2016-03-15 | 2020-04-24 | 浙江大学 | Amplification activation method of iNKT lymphocytes |
| CN105647864A (en) * | 2016-03-15 | 2016-06-08 | 浙江大学 | Amplification and activation method of iNKT (invariant natural killer T) lymphocyte |
| CN105695404B (en) * | 2016-03-15 | 2020-02-07 | 浙江大学 | Amplification activation method of CIK lymphocytes |
| CN105695404A (en) * | 2016-03-15 | 2016-06-22 | 浙江大学 | Method for amplifying and activating CIK lymphocyte |
| CN105647863A (en) * | 2016-03-15 | 2016-06-08 | 浙江大学 | Method for amplifying and activating LAK cells by non-fetus bovine serum |
| CN105647863B (en) * | 2016-03-15 | 2020-08-25 | 浙江大学 | Method for amplifying and activating LAK cells without fetal bovine serum |
| CN106497952A (en) * | 2016-11-03 | 2017-03-15 | 河南省华隆生物技术有限公司 | A kind of based on the film ankyrin of CD86, its preparation method and application |
| CN107177548B (en) * | 2017-06-26 | 2021-01-05 | 杭州中赢生物医疗科技有限公司 | Culture system for in vitro lymphocyte amplification, amplification method and application |
| CN107177548A (en) * | 2017-06-26 | 2017-09-19 | 杭州中赢生物医疗科技有限公司 | A kind of cultivating system of amplification in vitro lymphocyte and amplification method and application |
| CN110951684A (en) * | 2019-12-20 | 2020-04-03 | 吉林省中科生物工程股份有限公司 | Human peripheral blood NK cell culture system and culture method |
| CN112608901A (en) * | 2020-12-21 | 2021-04-06 | 广东昭泰体内生物医药科技有限公司 | Artificial antigen presenting cell and preparation method and application thereof |
| CN112608901B (en) * | 2020-12-21 | 2023-11-21 | 广东昭泰细胞生物科技有限公司 | Artificial antigen presenting cell, preparation method and application thereof |
| CN114686429A (en) * | 2020-12-31 | 2022-07-01 | 中国科学院分子细胞科学卓越创新中心 | Tumor immunotherapy method for activating NK cells |
| WO2022143938A1 (en) * | 2020-12-31 | 2022-07-07 | 中国科学院分子细胞科学卓越创新中心 | Tumor immunotherapy method based on activation of nk cell |
| CN114686429B (en) * | 2020-12-31 | 2024-03-26 | 中国科学院分子细胞科学卓越创新中心 | Tumor immunotherapy method for activating NK cells |
| CN114058584A (en) * | 2022-01-07 | 2022-02-18 | 山东省齐鲁干细胞工程有限公司 | Preparation method of natural killer cells for clinical use |
| CN115247149A (en) * | 2022-08-22 | 2022-10-28 | 华域生物科技(天津)有限公司 | Culture medium composition suitable for NK cells and culture method |
| RU2803178C1 (en) * | 2022-12-08 | 2023-09-07 | Общество с ограниченной ответственностью "Текон Медицинские приборы" | Recombinant cell line tmdk562-15 showing the ability to activate and proliferate human nk cells |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103232973B (en) | 2016-06-22 |
| CN102586185A (en) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103232973A (en) | Method for amplification and activation of NK cells by K562 cells | |
| CN107206100B (en) | Methods and compositions for natural killer cells | |
| Li et al. | Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy | |
| Chen et al. | Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus | |
| JP2023115069A (en) | Method and composition for gene editing in hematopoietic stem cell | |
| CN101735982A (en) | Method for amplifying lymphocyte by interleukin 15 receptor and interleukin 2 complex | |
| Del Prete et al. | Functional role of dendritic cell subsets in cancer progression and clinical implications | |
| CN103820393A (en) | Engineered CD20 targeting NKT cell and its preparation method and application | |
| CN109536455B (en) | CAR-NK cell and preparation method and application thereof | |
| CN106635987B (en) | A kind of method and its application of external efficient amplification NK cell | |
| Qin et al. | Chimeric antigen receptor beyond CAR-T cells | |
| CN105296431A (en) | Tumor binding specific gamma delta TCR gene modified alpha beta T cell and cancer suppression application thereof | |
| CN109055380A (en) | A kind of preparation method of universal CAR-T cell | |
| Levy et al. | RNA-seq analysis reveals CCR5 as a key target for CRISPR gene editing to regulate in vivo NK cell trafficking | |
| Morales et al. | Myeloid-derived suppressor cells enhance IgE-mediated mast cell responses | |
| Wang et al. | Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential | |
| Fernández et al. | Optimizing the procedure to manufacture clinical-grade NK cells for adoptive immunotherapy | |
| CN110016465A (en) | A kind of immunocyte drug comprising B cell and the double identity T cells of tumour | |
| Morimoto et al. | Natural killer cell-based immunotherapy against glioblastoma | |
| CN104894072A (en) | Preparation method and application of autologous natural killer cell proliferation | |
| CN106957822B (en) | Culture method, kit and application of in-vitro amplified gene editing activated T cells | |
| CN111518834B (en) | CAR-T cell and preparation method and medicament thereof | |
| CN102154207B (en) | Method for amplifying and activating lymphocyte by using CD8 alpha-interleukin 21-CD137 compound | |
| CN107502589A (en) | A kind of tumor infiltrating lymphocyte and mononuclearcell co-culture method | |
| da Silva et al. | The war is on: the immune system against glioblastoma—how can nk cells drive this battle? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: HANGZHOU ZHONGYING TECHNOLOGY GROUP CO., LTD. Free format text: FORMER OWNER: ZHEJIANG ZHONGYING LIFE ARK BIOTECHNOLOGICAL ENGINEERING CO., LTD. Effective date: 20130830 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310000 HANGZHOU, ZHEJIANG PROVINCE TO: 310052 HANGZHOU, ZHEJIANG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20130830 Address after: 310052 No. 88 Chutian Road, Hangzhou, Zhejiang, Binjiang District Applicant after: Hangzhou Zhongying Technology Group Co., Ltd. Address before: Hangzhou City, Zhejiang province 310000 Binjiang District West Street (pro) Chutian Road No. 88 Applicant before: Zhejiang Zhongying Life Ark Biological Engineering Co., Ltd. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151224 Address after: 310052 No. 88 Chutian Road, Hangzhou, Zhejiang, Binjiang District Applicant after: Hangzhou Zhongying bio-medical technology limited company Address before: 310052 No. 88 Chutian Road, Hangzhou, Zhejiang, Binjiang District Applicant before: Hangzhou Zhongying Technology Group Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |